Related Experiment Videos
[High-dose chemotherapy: principles, indications and complications].
U Göbel1, H Jürgens, D Schwamborn
1Abteilung für Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Universität Düsseldorf.
Klinische Padiatrie
|January 1, 1988
Summary
Systemic chemotherapy has improved cure rates in pediatric cancers over the last 15 years. High-dose regimens effectively treat resistant tumors, with strategies to manage severe complications.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Clinical Trials
Context:
- Significant advancements in treating childhood and adolescent malignant diseases.
- Systemic chemotherapy introduction in cooperative trials has led to improved cure rates.
- Recent 10-15 years show notable progress in pediatric cancer treatment outcomes.
Purpose:
- To discuss the rationale behind using high-dose chemotherapy regimens.
- To outline methods for protecting patients from severe complications.
- To highlight the efficacy of high-dose regimens for resistant tumors.
Summary:
- Improved cure rates in pediatric and adolescent cancers are linked to systemic chemotherapy in cooperative trials.
- Tumors previously resistant to conventional doses show positive responses to high-dose regimens.
- The study explores the justification for high-dose therapy and protective measures against its complications.
Impact:
- High-dose chemotherapy regimens offer a viable treatment option for resistant pediatric cancers.
- Effective management strategies mitigate life-threatening complications associated with high-dose therapy.
- Enhanced understanding of high-dose regimens contributes to better outcomes in pediatric oncology.